For patients at higher risk of recurrence and metastatic disease (stages IIB and IIC), one year of adjuvant immunotherapy treatment with programmed cell death receptor 1 (PD-1) blockade (pembrolizumab or nivolumab) is recommended. Here, PDCD1 is linked to metastatic neoplasm.